Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30.
A thirty amino acid synthetic peptide (HGP30) representing the conserved region of HIV-1 p17 induced high titer antibodies to the native p17 in rabbits. This immune sera neutralized HIV-1 replication in cell culture and one of the high titer antisera also inhibited CD4-dependent cell fusion. Pepscan analysis with overlapping nonapeptides derived from the sequence of HIV-1 p17 identified the sequence (KE) ALDKIEE (EQ) as the major antibody binding site. Sera of 9% of AIDS patients (7/76) and 18% of HIV-1 seropositive healthy homosexuals (40/223) were positive for HGP30 antibodies. Decline in HIV-1 p17 antibodies has been shown to be related to disease progression in both children and adults, suggesting that HIV-1 p17 antibodies may be protective. Hence, a synthetic HIV-1 p17 peptide, representing the immunodominant epitope, could be useful as a candidate vaccine for immunization of HIV-1 seronegative or seropositive healthy homosexuals.
Human Retrovirus Laboratory, University of Amsterdam, The Netherlands.
C A
CA
Boucher
W J
WJ
Krone
J
J
Goudsmit
R H
RH
Meloen
P H
PH
Naylor
A L
AL
Goldstein
D K
DK
Sun
P S
PS
Sarin
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D000939:Epitopes; D015483:HIV Antibodies / Q000096:biosynthesis*; D015488:HIV Antigens / Q000276:immunology*; D006679:HIV Seropositivity / Q000276:immunology; D006801:Humans; D008969:Molecular Sequence Data; D010455:Peptides / Q000276:immunology*; D011817:Rabbits; D014765:Viral Vaccines / Q000276:immunology* / Q000627:therapeutic use; D054301:gag Gene Products, Human Immunodeficiency Virus
D000939:Epitopes; C052407:HGP-30 peptide, Human immunodeficiency virus-1; D015483:HIV Antibodies; D015488:HIV Antigens; D010455:Peptides; D014765:Viral Vaccines; D054301:gag Gene Products, Human Immunodeficiency Virus